New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment

Marc Ladanyi, Marjorie G. Zauderer, Lee M. Krug, Tatsuo Ito, Robert McMillan, Matthew Bott, Filippo Giancotti

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Malignant pleural mesothelioma (MPM) is a highly lethal cancer with limited therapeutic options. Recent work has focused on the frequent somatic inactivation of two tumor suppressor genes in MPM-NF2 (Neurofibromatosis type 2) and the recently identified BAP1 (BRCA associated protein 1). In addition, germline mutations in BAP1 have been identified that define a new familial cancer syndrome, which includes MPM,ocular melanoma, and other cancers. These recent advances may allow screening of high-risk individuals and the development of new therapies that target key pathways in MPM.

Original languageEnglish
Pages (from-to)4485-4490
Number of pages6
JournalClinical Cancer Research
Volume18
Issue number17
DOIs
Publication statusPublished - Sep 1 2012

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment'. Together they form a unique fingerprint.

  • Cite this